ZLAB · XBRL financial data

Zai Lab financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ZLAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	66*	87	101	102	109*	106	110	116	128*	100	106	108
Revenue from contracts with customers	66*	87	100	102	109*	106	109	115	127*	96	106	108
Cost of revenue	25*	34	—	—	—	—	—	—	—	—	—	—
Cost of goods and services sold	25*	34	35	37	42*	38	43	47	62*	38	48	51
Research and development	82*	55	62	66	52*	61	51	48	62*	66	62	50
Selling, general and administrative	83*	69	80	67	83*	63	71	70	73*	65	73	70
Operating income (loss)	(124)*	(70)	(76)	(68)	(68)*	(56)	(55)	(49)	(69)*	(69)	(76)	(63)
Interest income	10*	10	9	9	9*	9	9	8	7*	6	6	6
Interest expense	0*	0	0	1	1*	1	1	1	1*	2	2	2
Other income (expense)	7*	9	(9)	3	1*	(0)	4	(1)	0*	0	5	0
Income tax expense (benefit)	0*	0	0	0	0*	0	0	0	(3)*	1	(1)	(2)
Net income (loss)	(95)*	(53)	(80)	(42)	(82)*	(48)	(41)	(36)	(50)*	(51)	(51)	(46)
Earnings per share, basic USD per share	(0.10)*	(0.05)	(0.08)	(0.04)	(0.08)*	(0.04)	(0.04)	(0.03)	(0.05)*	(0.05)	(0.05)	(0.04)
Earnings per share, diluted USD per share	(0.10)*	(0.05)	(0.08)	(0.04)	(0.08)*	(0.04)	(0.04)	(0.03)	(0.05)*	(0.05)	(0.05)	(0.04)
Weighted average shares, basic millions of shares	970*	973	976	982	1,027*	1,081	1,092	1,102	1,106*	1,107	1,117	1,123
Weighted average shares, diluted millions of shares	970*	973	976	982	1,027*	1,081	1,092	1,102	1,106*	1,107	1,117	1,123

Fiscal quarters (ZLAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	790	651	630	616	450	757	732	717	680	651	608	550
Short-term investments	16	0	0	0	330	0	0	0	10	10	10	10
Accounts receivable	59	60	70	50	85	77	88	85	106	54	70	65
Inventory	45	38	42	40	40	53	62	67	75	86	91	85
Prepaid and other current assets	23	24	20	36	42	44	41	44	37	35	33	44
Total current assets	940	889	870	861	1,050	1,042	1,034	1,033	1,019	945	914	864
Property and equipment, net	54	52	51	51	48	50	50	49	47	47	46	46
Right-of-use asset	15	15	13	13	21	19	17	16	19	18	16	15
Total assets	1,036	988	987	985	1,186	1,173	1,164	1,159	1,172	1,096	1,075	1,024
Accounts payable	113	88	127	121	101	103	107	100	142	126	137	120
Total current liabilities	203	192	252	286	299	320	332	360	416	393	429	424
Lease liability, non-current	8	8	6	6	14	12	11	11	13	12	11	10
Total liabilities	240	226	283	318	345	363	372	399	457	434	468	461
Accumulated deficit	(2,196)	(2,249)	(2,330)	(2,371)	(2,453)	(2,502)	(2,542)	(2,578)	(2,629)	(2,680)	(2,730)	(2,777)
Total stockholders' equity	796	762	704	668	841	811	792	760	716	662	607	563
Total liabilities and equity	1,036	988	987	985	1,186	1,173	1,164	1,159	1,172	1,096	1,075	1,024
Common shares outstanding (cover page) millions of shares	972	973	981	984	1,078	1,084	1,099	1,106	1,106	1,110	1,122	1,124

Fiscal quarters (ZLAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(95)*	(53)	(80)	(42)	(82)*	(48)	(41)	(36)	(50)*	(51)	(51)	(46)
Stock-based compensation	20*	18	19*	17*	17*	16	17*	17*	16*	14	12*	11*
Depreciation and amortization	2*	3	3*	3*	3*	3	4*	4*	4*	4	4*	4*
Net cash from operating activities	(15)*	(90)	(42)*	(27)*	(56)*	(62)	(31)*	(32)*	(26)*	(12)	(63)*	(58)*
Purchases of property and equipment	0*	1	1*	1*	3*	2	3*	3*	1*	1	1*	1*
Net cash from investing activities	14*	3	(1)*	(30)*	(348)*	326	(3)*	(4)*	(11)*	(22)	(1)*	(13)*
Proceeds from issuing common stock	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from financing activities	0*	48	22*	42*	238*	43	9*	21*	(0)*	6	19*	14*
Net change in cash	1*	(39)	(21)*	(14)*	(166)*	308	(25)*	(15)*	(38)*	(28)	(44)*	(58)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Zai Lab	550	108	(58)*	not reported	12.3 quarters	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	125	not reported	(224)*	158.3M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
PERRIGO	437	989	96*	138.8M	—	Q3 FY26 10-QSep 26, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	125	141	17*	221.9M	—	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	150	173	(43)*	101.9M	2.3 quarters	Q3 FY26 10-QSep 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.